Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.

Moreau P, Giralt SA.

Leuk Res. 2012 Nov;36 Suppl 1:S13-8. doi: 10.1016/S0145-2126(12)70004-8. Review.

PMID:
23176719
[PubMed - indexed for MEDLINE]
2.

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.

Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, Hose D, Kunz C, Heiß C, Ho AD, Goldschmidt H, Hillengass J.

Ann Oncol. 2014 Jan;25(1):189-95. doi: 10.1093/annonc/mdt509.

PMID:
24356629
[PubMed - indexed for MEDLINE]
3.

ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.

Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Savini A, Alesiani F, Brunori M, Catarini M, Visani G, Samori A, Burattini M, Centurioni R, Montanari M, Fraticelli P, Ruggieri M, Falcioni S, Galieni P.

Eur J Haematol. 2010 Jun;84(6):474-83. doi: 10.1111/j.1600-0609.2010.01418.x. Epub 2010 Mar 11.

PMID:
20331733
[PubMed - indexed for MEDLINE]
4.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL.

Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.

PMID:
21849487
[PubMed - indexed for MEDLINE]
Free Article
5.

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-López J, Mateos MV, Cibeira MT, Cordón L, Oriol A, Terol MJ, Echeveste MA, de Paz R, de Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martin A, Hernández MT, Lahuerta JJ, Bladé J, San Miguel JF; PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups.

Blood. 2012 Jan 19;119(3):687-91. doi: 10.1182/blood-2011-07-370460. Epub 2011 Nov 29.

PMID:
22128143
[PubMed - indexed for MEDLINE]
Free Article
6.

Evolving therapeutic paradigms for multiple myeloma: back to the future.

Cherry BM, Korde N, Kwok M, Roschewski M, Landgren O.

Leuk Lymphoma. 2013 Mar;54(3):451-63. doi: 10.3109/10428194.2012.717277. Epub 2012 Sep 14. Review.

PMID:
22880935
[PubMed - indexed for MEDLINE]
7.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

PMID:
21411441
[PubMed - indexed for MEDLINE]
Free Article
8.

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.

PMID:
19285634
[PubMed - indexed for MEDLINE]
9.

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

Roussel M, Facon T, Moreau P, Harousseau JL, Attal M.

Recent Results Cancer Res. 2011;183:189-206. doi: 10.1007/978-3-540-85772-3_9. Review.

PMID:
21509686
[PubMed - indexed for MEDLINE]
10.

The role of autologous stem cell transplantation in the management of multiple myeloma.

Fermand JP, Brechignac S.

Pathol Biol (Paris). 1999 Feb;47(2):199-202. Review.

PMID:
10192889
[PubMed - indexed for MEDLINE]
11.

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.

PMID:
21789621
[PubMed - indexed for MEDLINE]
12.

Treatment of multiple myeloma.

San Miguel JF, Bladé Creixenti J, García-Sanz R.

Haematologica. 1999 Jan;84(1):36-58. Review.

PMID:
10091392
[PubMed - indexed for MEDLINE]
Free Article
13.

Evolving role of stem cell transplantation in multiple myeloma.

Harousseau JL, Moreau P.

Clin Lymphoma Myeloma. 2005 Sep;6(2):89-95. Review.

PMID:
16231846
[PubMed - indexed for MEDLINE]
14.

Multiple myeloma.

Dimopoulos MA, Terpos E.

Ann Oncol. 2010 Oct;21 Suppl 7:vii143-50. doi: 10.1093/annonc/mdq370. Review.

PMID:
20943607
[PubMed - indexed for MEDLINE]
Free Article
15.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
[PubMed - indexed for MEDLINE]
Free Article
16.

Role of autologous bone marrow transplant in multiple myeloma.

Blanes M, de la Rubia J.

Curr Opin Oncol. 2012 Nov;24(6):733-41. doi: 10.1097/CCO.0b013e328358f686. Review.

PMID:
23079784
[PubMed - indexed for MEDLINE]
17.

The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.

Kyle RA.

Ann Oncol. 2000;11 Suppl 1:55-8. Review.

PMID:
10707780
[PubMed - indexed for MEDLINE]
18.

Sustained disease control in transplant-ineligible patients: the role of continuous therapy.

Palumbo A, Niesvizky R.

Leuk Res. 2012 Nov;36 Suppl 1:S19-26. doi: 10.1016/S0145-2126(12)70005-X.

PMID:
23176720
[PubMed - indexed for MEDLINE]
19.

Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis.

Faussner F, Dempke WC.

Anticancer Res. 2012 May;32(5):2103-9.

PMID:
22593496
[PubMed - indexed for MEDLINE]
20.

[Intensive treatment of multiple myeloma].

Harousseau JL.

Bull Acad Natl Med. 2003;187(2):405-13; discussion 413-5. Review. French.

PMID:
14556449
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk